Sosei Group Corporation Subsidiary Heptares Awarded $5.5 Million Research & Development Grant From National Institute on Drug Abuse (NIDA)

Published: Sep 28, 2015

TOKYO--(BUSINESS WIRE)--Sosei Group Corporation (“Sosei”; TOKYO:4565) is pleased to announce that its wholly-owned subsidiary Heptares Therapeutics (“Heptares”) has been awarded a grant from the National Institute on Drug Abuse (NIDA), one of the US National Institutes of Health. The grant of approximately $5.5 million, with additional funding from Heptares, will support a three-year research project aimed at developing a selective antagonist for the human Orexin-1 receptor for use in treating cocaine addiction and dependence, for which there are currently no approved treatments.

Help employers find you! Check out all the jobs and post your resume.

Back to news